Roy Baynes, MD, PhD
Japan’s Pharmaceuticals and Medical Devices Agency has approved lenvatinib mesylate (Lenvima) for the frontline treatment of patients with unresectable hepatocellular carcinoma (HCC).
Merck and Eisai announced in September 2017 that the US FDA had accepted a supplemental new drug application for frontline lenvatinib in HCC.
Cheng A-L, Finn RS, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35 (suppl; abstr 4001).
... to read the full story